Stivarga: a new oral multikinase inhibitor

Stivarga (regorafenib) is indicated in metastatic colorectal cancer previously treated with fluoropyrimidine-based chemotherapy, anti-VEGF therapy and anti-EGFR therapy, or when these therapies are not suitable.

by
The recommended dose of Stivarga is 160mg once daily after a light low-fat meal on days 1-21 of a 28-day treatment cycle
The recommended dose of Stivarga is 160mg once daily after a light low-fat meal on days 1-21 of a 28-day treatment cycle

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package